Navigation Links
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Date:9/24/2008

rase inhibitor.

About ANA598

Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA), subsequent allowance of the IND by the FDA and initiation of clinical investigation in the second quarter of 2008. In the preclinical program, ANA598 was well tolerated at all doses tested in 28-day GLP toxicology studies. Furthermore, ANA598 was shown to be active in a primate model of chronic HCV infection, leading to a greater than 2 log viral load decline in each of two genotype 1b infected animals. Anadys has previously reported data demonstrating that ANA598 retains undiminished activity against a number of HCV variants resistant to other direct antivirals currently in development.

Clinical Need and Market Opportunity in HCV Infection

Chronic HCV infection is a serious public health concern affecting approximately 3.2 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection,

it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV. The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. Most infected individuals ar
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
2. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
7. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
8. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
11. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... at 8 am versus placebo: - 25,/ - ... Blood pressure reduction dependent on vaccine dose and ... today at the Seventeenth European,Meeting on Hypertension in ... Italy, June 17, 2007 -,Cytos Biotechnology AG (SWX:CYTN) ...
... WIRE)--Jun 18, 2007 - Advanced Viral,Research Corp. ... today that preliminary findings from its ongoing,Phase ... AVR118,appears to have clinical activity in reducing ... dermatologic,dermabrasion., The Phase II open label dermatological ...
Cached Medicine Technology:Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2
(Date:1/22/2015)... (PRWEB) January 23, 2015 The U.S. ... R.Ph., DICVP, Director of Clinical Pharmacy Services at North ... the recipient of the 2015 Beal Award for Distinguished ... USP has relied on the contributions of volunteer experts ...
(Date:1/22/2015)... 2015 Gabe’s Chemo Duck Program is pleased to ... app ever created for kids with cancer. The Chemo Duck App, ... is filled with enjoyable games to help children of all ages ... app helps to keep kids entertained, educated and at ease while ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... seek medical treatment to correct the malady, a media report ... erectile problems affected 50 percent of men over 50 in ... Post said. ,But Andrew Yip Wai-chun, honorary consultant ... of Hospitals, who released details of the study, said just ...
... a key enzyme responsible for triggering a chain of ... study findings published online// this week in Nature Immunology. ... University, the Hospital for Special Surgery and Weill Cornell ... development of new strategies and target therapies that control ...
... who have close relatives suffering from breast cancer but who ... illness may still have a// higher than average risk of ... they may test negative for the BRCA1 and BRCA2 faults, ... with breast cancer by the age of 50 than other ...
... A heart specialist from down under has experimented with a ... clear blocked arteries. This could prove a blessing for// the ... blocks in their arteries. ,Heart stents are no ... of heart attacks and open heart surgeries. Yet stents have ...
... auctioning off fighters in pink race gear on e Bay ... is the Breast Cancer Awareness month and pink is// the ... in collaboration with PKV Racing to create exclusive warriors in ... are all accessible at the eBay auction. ,Parts ...
... who got her breasts pierced for her 18th birthday suffered ... doctors to surgically remove her left// breast. Surgeons had to ... Edington’s collar bone last week at the Indiana University Medical ... who examined Edington diagnosed her to with gas gangrene or ...
Cached Medicine News:Health News:Key Signaling Switch Identified in Allergic Disease 2Health News:Breast Cancer linked to Gene Risk 2
A rapid, convenient, qualitative method for detecting asymptomatic occult bleeding....
... die each year of colon cancer ... improvements (high contrast berium enema, colonoscopy, ... in the success rate of curative ... been achieved over the past two ...
... of guaiac as a test for the presence ... phenolic compounds present in guaiac to quinones, resulting ... blood is present, the heme portion of the ... catalyzing the release of oxygen from hydrogen peroxide ...
... elitewas designed to improve patient compliance. Its ... sample collection options make this fecal occult ... and complete. Diet guidelines are explained in ... which foods and drugs are okay and ...
Medicine Products: